It is well known that abnormal lipid metabolism in obesity is regarded as a major driving force for dyslipidemia and hepatic steatosis, and insulin resistance and inflammation play an important role in the development of dyslipidemia and hepatic steatosis [2]. This evidence concerns the gene INS and metabolic syndrome.